China CCM: Polycystic Ovarian Syndrome -Drug Pipeline Analysis and Market Forecasts to 2016

Oct. 12, 2010 - PRLog -- GlobalData, the industry analysis specialist's new report, "Polycystic Ovarian Syndrome-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global polycystic ovarian syndrome market. The report identifies the key trends shaping and driving the global polycystic ovarian syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global polycystic ovarian syndrome sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The report provides information on the key drivers and challenges of the global polycystic ovarian syndrome market. Its scope includes:  
-Annualized global polycystic ovarian syndrome market revenues data from 2001 to 2009, forecast for seven years to 2016.
-Key geographies covered in this report are the US, the UK, Italy, Spain, Germany, France and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include fat breakdown inhibitors, estrogen antagonists, female gamete enhancers, insulin secretion stimulators, gastric lipase inhibitor HMG CoA inhibitors.
-Analysis of the current and future market competition in the global polycystic ovarian syndrome market. Key market players covered include Sanofi Aventis, Bristol Myers Squibb, Novartis Pharmaceuticals, Sandoz Inc, Genpharm Inc, Ivax Pharmaceuticals Inc, Barr Laboratories Inc, Par Pharmaceuticals Inc. Genpharm Inc, Merck CoA and Catalysis SL.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future polycystic ovarian syndrome market.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global polycystic ovarian syndrome market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global polycystic ovarian syndrome market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global polycystic ovarian syndrome market landscape? -Identify, understand and capitalize.



Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Polycystic Ovarian Syndrome Market: Market Characterization 6
2.1 Market Overview 6
2.2 Polycystic Ovarian Syndrome Market Size 6
2.3 Polycystic Ovarian Syndrome Market forecast and CAGR 7
2.4 Drivers and Barriers for Polycystic Ovarian Syndrome Market 8
2.4.1 Drivers for Polycystic Ovarian Syndrome market 8
2.4.2 Barriers for Polycystic Ovarian Syndrome market 10
2.5 Opportunity and Unmet Need 11
2.6 Key Takeaway 12
3 Polycystic Ovarian Syndrome Market: Competitive Assessment 13
3.1 Overview 13
3.2 Strategic Competitor Assessment 13
3.3 Product Profile for The Marketed Drugs For Polycystic Ovarian Syndrome 14
3.3.1 Clomid 14
3.4 Product Profile for Off-Label Drugs for Polycystic Ovarian Syndrome 16
3.4.1 Metformin 16
3.4.2 Letrozole 17
3.4.3 Flutamide 18
3.5 Key Takeaway 20
4 Polycystic Ovarian Syndrome Market: Pipeline Assessment 21
4.1 Overview 21
4.2 Strategic Pipeline Assessment 21
4.2.1 Technology Trends Analytic Framework 21
4.3 Profile of Pipeline Molecules in Clinical Development 22
4.3.1 Metformin+exenatide 22
4.3.2 Follitropin alfa liquid formulation 23
4.3.3 Human Gonadotropin Hormone 23
4.3.4 Simvastatin 23
4.3.5 Orlistat 24
4.3.6 Clomiphene citrate+raloxifene 25
4.3.7 Oral DCI 25
4.3.8 Sibutramine+Loestrin (ethinyl estradiol) 25
4.3.9 Leuprolide acetate+Spironolactone 26
4.3.10 Oral Cinnamon Extract 26
4.3.11 Oral contraceptive 26
4.3.12 Dietary Supplement: Diamel 26
4.3.13 Dietary Supplement: Flaxeed 27
4.3.14 Dietary Supplement: Alpha Lipoic Acid 27
4.3.15 Dietary Supplement: Vitamin D 27
4.4 Polycystic Ovarian Syndrome Market-Clinical Pipeline by Mechanism of Action 28
4.5 Polycystic Ovarian Syndrome Pipeline-Pipeline by Clinical Phases of Development 29
4.5.1 Polycystic Ovarian Syndrome Market-Phase III Clinical Pipeline 30
4.5.2 Polycystic Ovarian Syndrome Market-Phase II Clinical Pipeline 31
4.5.3 Polycystic Ovarian Syndrome Market-Phase I Clinical Pipeline 31
4.6 Key takeaway 31
5 Polycystic Ovarian Syndrome Market: Implications for Future Market Competition 32
6 Polycystic Ovarian Syndrome Market: Future Players in Polycystic Ovarian Syndrome Market 33
6.1 Merck KGaA 33
6.1.1 Company Overview 33
6.1.2 Business Description 33
6.1.3 Female Sexual Dysfunction Portfolio 34
6.2 Catalysis SL 35
6.2.1 Company overview 35
6.2.2 Female Sexual Dysfunction Portfolio 35
7 Polycystic Ovarian Syndrome Market: Appendix 36
7.1 Definitions 36
7.2 Acronyms 36
7.3 Research Methodology 36
7.3.1 Coverage 37
7.3.2 Secondary Research 37
7.3.3 Forecasting 38
7.3.4 Primary Research 40
7.3.5 Expert Panel Validation 41
7.4 Contact Us 41
7.5 Disclaimer 41
7.6 Sources 41

List of Tables
1.1 List of Tables
Table 1: Polycystic Ovarian Syndrome Market, Revenue ($m), 2001-2009 7
Table 2: Polycystic Ovarian Syndrome Market, Revenue ($m), 2009-2016 8
Table 3: Major Marketed Products Comparison in the Polycystic Ovarian Syndrome Market, 2010 19
Table 4: Polycystic Ovarian Syndrome Market-Phase III Clinical Pipeline, 2010 30
Table 5: Polycystic Ovarian Syndrome Market-Phase II Clinical Pipeline, 2010 31
Table 6: Polycystic Ovarian Syndrome Market-Phase I Clinical Pipeline, 2010 31
Table 7: Merck Pharmaceuticals-Female Sexual Dysfunction Marketed Products, 2010 34
Table 8: Merck Pharmaceuticals-Female Sexual Dysfunction Pipeline Products, 2010 34
Table 9: Catalysis SL-Female Sexual Dysfunction Marketed Products, 2010 35
Table 10: Catalysis SL-Female Sexual Dysfunction Pipeline Products, 2010 35

List of Figures
1.2 List of Figures
Figure 1:  Polycystic Ovarian Syndrome Market, Revenue ($m), 2001-2009 7
Figure 2:  Polycystic Ovarian Syndrome Market, Revenue ($m), 2009-2016 8
Figure 3:  Opportunity and Unmet Need for Polycystic Ovarian Syndrome Market, 2010 11
Figure 4:     Strategic Competitor Assessment of the Major Marketed Products in Polycystic Ovarian Syndrome Market, 2010 14
Figure 5:     Technology Trends Analytic Framework of the Polycystic Ovarian Syndrome Pipeline, 2010 21
......

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.